JP2024503894A - 粘膜がんを治療するための共生ウイルスに対するｔ細胞誘導性抗がんワクチン - Google Patents

粘膜がんを治療するための共生ウイルスに対するｔ細胞誘導性抗がんワクチン Download PDF

Info

Publication number
JP2024503894A
JP2024503894A JP2023544048A JP2023544048A JP2024503894A JP 2024503894 A JP2024503894 A JP 2024503894A JP 2023544048 A JP2023544048 A JP 2023544048A JP 2023544048 A JP2023544048 A JP 2023544048A JP 2024503894 A JP2024503894 A JP 2024503894A
Authority
JP
Japan
Prior art keywords
cancer
hpv
cell
composition
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503894A5 (https=
Inventor
デメーリ，シャドメア
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2024503894A publication Critical patent/JP2024503894A/ja
Publication of JP2024503894A5 publication Critical patent/JP2024503894A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023544048A 2021-01-21 2022-01-21 粘膜がんを治療するための共生ウイルスに対するｔ細胞誘導性抗がんワクチン Pending JP2024503894A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163140159P 2021-01-21 2021-01-21
US63/140,159 2021-01-21
PCT/US2022/013228 WO2022159652A1 (en) 2021-01-21 2022-01-21 T cell-directed anti-cancer vaccines against commensal viruses for treating mucosal carcinomas

Publications (2)

Publication Number Publication Date
JP2024503894A true JP2024503894A (ja) 2024-01-29
JP2024503894A5 JP2024503894A5 (https=) 2025-01-29

Family

ID=82549772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544048A Pending JP2024503894A (ja) 2021-01-21 2022-01-21 粘膜がんを治療するための共生ウイルスに対するｔ細胞誘導性抗がんワクチン

Country Status (4)

Country Link
US (1) US20240100141A1 (https=)
EP (1) EP4281106A4 (https=)
JP (1) JP2024503894A (https=)
WO (1) WO2022159652A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502486A (ja) * 2007-11-02 2011-01-27 ザ ジョンズ ホプキンス ユニバーシティ ヒトパピローマウイルス感染症の治療又は予防のための複数型ｈｐｖペプチド組成物及び方法
WO2020112720A1 (en) * 2018-11-28 2020-06-04 The General Hospital Corporation T cell-directed anti-cancer vaccines against commensal viruses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502486A (ja) * 2007-11-02 2011-01-27 ザ ジョンズ ホプキンス ユニバーシティ ヒトパピローマウイルス感染症の治療又は予防のための複数型ｈｐｖペプチド組成物及び方法
WO2020112720A1 (en) * 2018-11-28 2020-06-04 The General Hospital Corporation T cell-directed anti-cancer vaccines against commensal viruses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE, vol. 575, JPN6025047609, 30 October 2019 (2019-10-30), pages 519 - 522, ISSN: 0005738257 *

Also Published As

Publication number Publication date
WO2022159652A1 (en) 2022-07-28
EP4281106A4 (en) 2024-12-25
US20240100141A1 (en) 2024-03-28
EP4281106A1 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
Wang et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine
Khairkhah et al. Current and future direction in treatment of HPV-related cervical disease
ES2876152T3 (es) Generación de células T específicas del VPH
ES2253636T3 (es) Vacuna contra hpv.
Cladel et al. Mouse papillomavirus MmuPV1 infects oral mucosa and preferentially targets the base of the tongue
JP7688576B6 (ja) 共生ウイルスに対するｔ細胞指向性抗がんワクチン
Tchernev Sexually transmitted papillomavirus infections: epidemiology pathogenesis, clinic, morphology, important differential diagnostic aspects, current diagnostic and treatment options
JP2011037902A (ja) パピローマウイルス感染の治療方法
TW202140069A (zh) Hpv疫苗
US20130034584A1 (en) Agent for use in the topical or local treatment of cervical dysplasias
Hu et al. An HLA-A2. 1-transgenic rabbit model to study immunity to papillomavirus infection
CN108126204A (zh) 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法
US20240100141A1 (en) T cell-directed anti-cancer vaccines against commensal viruses for treating mucosal carcinomas
KR100904844B1 (ko) 인유두종 바이러스（ｈｐｖ）유전자를 포함하는자궁경부암의 치료 또는 예방용 ｄｎａ 백신
JP4854742B2 (ja) 抗ｈｐｖ感染症薬の調製におけるノカルディア・ルブラ細胞壁骨格の使用
Gall Human papillomavirus infection and therapy with interferon
RU2377305C1 (ru) Мукозальная вакцина для иммунотерапии заболеваний, обусловленных вирусами папилломы человека, и способ лечения с ее использованием (варианты)
BR112012004928A2 (pt) sequência de ácido nucléico isolada, vetor de expressão, composição imunogenica sinérgica que compreende um vetor de expressão que codifica a proteína e7 do vírus do papiloma humano (hpv) fusionada à proteína gd do vírus herpes humano tipo 1 (hsv-1) e um vetor de expressão que codifica uma citocina e seus usos
Al-Azmi et al. Human papillomavirus: manifestations, prevention and treatment: an overview
JP2013512914A (ja) ヒトパピローマウイルス（ｈｐｖ）により発症された腫瘍性又は癌性病変に対するワクチン、処置、用途及び方法
US9308237B2 (en) Papillomavirus virus-like particle or capsomere formulation and its use as microbicide
JP2025506695A (ja) ｍＲＮＡワクチン
Valerie et al. Recurrent respiratory papillomatosis: an extensive review
EA047059B1 (ru) Вакцина против hpv
South et al. 19 Preventive strategies and non-invasive treatment options for cervical pre-invasive and invasive disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225